S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Astellas Pharma Stock Price, News & Analysis (OTCMKTS:ALPMY)

$12.28
+0.12 (+0.99%)
(As of 12/1/2023 ET)
Compare
Today's Range
$11.75
$12.28
50-Day Range
$11.57
$14.44
52-Week Range
$11.25
$16.91
Volume
191,640 shs
Average Volume
324,764 shs
Market Capitalization
$22.22 billion
P/E Ratio
102.34
Dividend Yield
1.22%
Price Target
N/A

Astellas Pharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.53mentions of Astellas Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
22.39%
From $0.67 to $0.82 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars


ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
ALPMY Astellas Pharma Inc.
Pittsboro firm with 5 employees sold for $175M
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Astellas Pharma To Buy Propella Therapeutics For About $175 Mln
Astellas to Acquire Propella Therapeutics
Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/02/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

Net Income
$742 million
Pretax Margin
8.71%

Debt

Sales & Book Value

Annual Sales
$11.24 billion
Cash Flow
$1.37 per share
Book Value
$6.25 per share

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$22.22 billion
Optionable
Not Optionable
Beta
0.50

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 61)
    President, CEO & Director
    Comp: $963.45k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 56)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 60)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive














ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALPMY shares.
View ALPMY analyst ratings
or view top-rated stocks.

How have ALPMY shares performed in 2023?

Astellas Pharma's stock was trading at $15.16 at the start of the year. Since then, ALPMY stock has decreased by 19.0% and is now trading at $12.28.
View the best growth stocks for 2023 here
.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in October. As of October 31st, there was short interest totaling 48,000 shares, an increase of 1,197.3% from the October 15th total of 3,700 shares. Based on an average daily trading volume, of 792,600 shares, the days-to-cover ratio is presently 0.1 days.
View Astellas Pharma's Short Interest
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.17 by $0.18. The firm earned $2.71 billion during the quarter. Astellas Pharma had a net margin of 2.06% and a trailing twelve-month return on equity of 8.74%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.15 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 125.01%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ALPMY will have a dividend payout ratio of 18.29% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Astellas Pharma's stock split?

Astellas Pharma's stock split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -